All Data Analysis articles – Page 2
-
NewsUK ‘gaining pace’ with early-stage trials for advanced therapies
CGT Catapult research shows an increase in phase I/II trials, led by oncology but with clear growth in other disease areas such as inflammation.
-
NewsHoth Therapeutics’ topical therapy shines in cancer toxicity trial
Achieves 100 percent response in phase II data highlighting HT-001's potential as a supportive oncology treatment to address a common EGFR therapy burden.
-
News
Biomanufacturing framework could boost microbial production efficiency
Research findings support the design of robust microbial processes for pharmaceutical products.
-
NewsJohnson & Johnson’s Caplyta demonstrates phase III promise for depression
Combination therapy comprising of an antidepressant and small molecule drug significantly boosted remission rates in adults with major depressive disorder.
-
News
Yeast research could advance sustainable pharmaceutical bioproduction
Novel approach holds potential to reduce the industry’s dependence on coconut and palm oil extraction for bioproduction of short- and medium-chain fatty acids.
-
NewsAI framework could enhance continuous manufacturing, say FDA researchers
Digital twin model offers potential for advanced control during continuous pharmaceutical manufacturing processes.
-
NewsEuropean Pharmacopoeia publishes new data quality framework
New general chapter on quality of data 5.38 supports stakeholders with digitalisation during pharmaceutical quality decision-making.
-
NewsNovartis chromatography study shows downstream purification benefits
The impurities research illustrates an approach that could offer a simpler and more flexible downstream purification process.
-
NewsJ&J’s Rybrevant-Lazcluze combination wins FDA first in lung cancer
US approval of the subcutaneous therapy provides a novel chemotherapy-free frontline option in EGFR-mutated NSCLC.
-
NewsAstraZeneca and Daiichi’s Enhertu wins first-in-decade US oncology approval
FDA approval of the drug in combination with Perjeta initiates a $150 million milestone payment to Daiichi Sankyo from AstraZeneca under their joint collaboration.
-
NewsCHMP recommends cancer medicines by SFL Pharmaceuticals and Serum Life Science Europe
The EMA’s human medicines committee also recommended approval of drugs by GSK, Moderna, STADA, Lupin Europe and Cytokinetics.
-
NewsOff-the-shelf dual-antibody immunotherapy shows myeloma potential
The combination of two J&J biologics demonstrates a significantly improved treatment response for the most aggressive form of multiple myeloma in new phase II data.
-
ArticleA four-step way out of pharma manufacturing's asset management struggles
Here, Hexagon outlines a four-step plan to address silos and scale-up challenges, drawing on the experience of leading pharma firms like Pfizer.
-
NewsImpurities findings could enhance peptide drug safety
EpiVax and Cubrc research supports FDA guidance on impurity risk assessment in generic peptides.
-
NewsGamida Cell wins cell therapy first in severe aplastic anaemia from FDA
The US approval for the Ayrmid company’s novel transplant option Omisirge adds to its existing licence in haematological malignancy.
-
NewsBristol Myers Squibb wins fifth US approval for CAR T cell therapy Breyanzi
The FDA’s latest authorisation makes it the most widely approved of any CD19-directed CAR T therapy in cancer.
-
News
J&J biologic Imaavy achieves EU first in generalised myasthenia gravis
The monoclonal antibody becomes the first neonatal Fc receptor (FcRn) blocker to be approved in Europe for the condition.
-
News
Regeneron and Tessera partner to develop gene therapy for AATD
The in vivo, one-time gene editing therapy has potential to transform outcomes for alpha-1 antitrypsin deficiency (AATD).
-
ArticleEuropean Pharmaceutical Review Issue 4 2025
EPR Issue 4 includes articles on manufacturing, AI/ML, vaccine development, biologics and more.
-
NewsAbbVie’s atogepant illustrates migraine therapy label expansion potential
If approved in Europe, atogepant would provide patients with a new acute treatment option for migraine attacks.